About Qingfeng
About Qingfeng Pharmaceutical
Qingfeng Pharmaceutical Group is a leading, innovation-driven pharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of high-quality medicines. Consistently ranked among China’s top 100 pharmaceutical companies, Qingfeng is widely recognized as an industry benchmark for pharmaceutical R&D excellence. The company has received numerous prestigious honors, including the Second Prize of the National Science and Technology Progress Award.
2500 +
Employee Headcount
50 +
Production Licenses (Last Five Years)
4
R&D Centers
60 +
Pipeline Products
18
National Tender Wins
3
Production Bases
End-to-End Industry Integration
R&D
Driven by innovation, we consistently reinvest at least 10% of our annual revenue into research and development. With collaborative innovation hubs in Shanghai, Beijing, Hangzhou, and Ganzhou, we have established a global and fully integrated R&D ecosystem that promotes open collaboration and cutting-edge advancements.
Explore more
R&D
Manufacturing
Our company operates three major production bases spanning nearly 466, 666 square meters. These facilities are built to meet U.S. Food and Drug Administration (US FDA) and EU's European Medicines Agency (EMA) standards, with highly automated and intelligent production lines. Our production bases are among the largest, most standardized, and most comprehensive pharmaceutical industrialization hubs in Central China.
Explore more
Manufacturing
Sales
Our sales team, composed of seasoned professionals, drives market expansion across China and into global markets. We have established an efficient sales network and a robust medical affairs system to ensure seamless distribution of high-quality pharmaceutical products, dedicated to meeting diverse healthcare needs worldwide.
Explore more
Sales
What Defines Us?
Building an Exceptional Company
Our Core Principles
Futurism, Long-Term Vision, and Value-Driven
Our Focus
Organizational Growth and Individual Development
Suraxavir Marboxil Tablets Approved for Market
In March 2025, our self-developed innovative drug, Suraxavir Marboxil Tablets (Class 1), was approved for market. It is indicated for the treatment of uncomplicated Type A and Type B influenza in healthy adolescents and adults aged 12 and older.
2025
Aurantii Fructus Immaturus Total Flavonoids Tablets Approved for Market
In October 2023, our self-developed Class 1.2 Traditional Chinese Medicine (TCM) innovative drug, Aurantii Fructus Immaturus Total Flavonoids Tablets, was approved by the National Medical Products Administration (NMPA) for the treatment of functional dyspepsia.
2023
Division of TCM and Chemical Medicine
In December 2021, Jiangxi Kvvit Pharmaceutical Co., Ltd. was established, marking the division of TCM and Chemical Medicine. The chemical drug business has been fully integrated into Kvvit Pharmaceutical, while the TCM business has been completely integrated into Qingfeng Pharmaceutical.
2021
Qingfeng Phase II Put into Production
In December 2019, the Phase II project of Qingfeng was put into production, marking the completion of a modern biopharmaceutical industrial base that integrates raw material drugs, Chinese medicine extraction, formulation production, and intelligent warehousing.
2019
Establishment of R&D Headquarters
In December 2016, the R&D headquarters, Shanghai Qingrun Pharmaceutical Technology Co., Ltd., was established, forming the foundation of our large R&D system.
2016
Corporate Group Transformation
In February 2014, Jiangxi Qingfeng Pharmaceutical Investment Group Co., Ltd. officially renamed to Qingfeng Pharmaceutical Group Co., Ltd., marking the transformation from a small regional manufacturer to a nationwide pharmaceutical enterprise.
2014
Clinical Research Expansion
In June 2010, the Beijing Clinical Registration Center and Hangzhou Drug R&D Center were established, creating platforms for clinical and global generic drug research and development.
2010
Towards Group Structure
In February 2008, Jiangxi Qingfeng Investment Group Co., Ltd. was formed, signifying the start of group-level operations.
2008
R&D and Marketing Development
In August 2005, the Prescription Drug Marketing Management Center was established in Shenzhen, creating a modern marketing system.
In January 2005, the Drug Research Center was founded, initiating the R&D layout.
2005
Restructuring and Relocation
In June 2001, Jiangxi Qingfeng Pharmaceutical Co., Ltd. underwent asset restructuring with Jiangxi Shanxiang Pharmaceutical Co., Ltd.
In May 2001, the company moved from Quannan County to Ganzhou Shahe Industrial Park and was renamed Jiangxi Qingfeng Pharmaceutical Co., Ltd.
2001
Foundation of Qingfeng
In September 1976, the predecessor of Qingfeng Pharmaceutical, Jiangxi Qingfeng Pharmaceutical Factory, was established under the Quannan Bayi Reclamation Farm. Established in an era of limited access to medicine, the company embarked on its mission to develop, produce, and deliver essential pharmaceuticals.
1976
Honorary Awards
Second Prize of the State Science and Technology Progress Award
China's top 100 pharmaceutical industry
The Most Growth-Oriented Enterprise in China's Pharmaceutical Industry
The Best Industrial Enterprise for Pharmaceutical R&D Product Lines in China
China Patent Excellence Award
National Exemplary Enterprises in the field of IPRs
National Technology Innovation Demonstration Enterprise
National Model Enterprise with Harmonious Labor Relations
Top 100 Chinese Medicine Brands
National High-Tech Enterprise
Load More
Member Enterprises
Jiangxi Kvvit Pharmaceutical Co., Ltd.
As a wholly owned subsidiary of Qingfeng Pharmaceutical Group, kvvit Pharmaceutical boasts a global, full-chain innovation R&D and pharmaceutical commercialization system.
The company operates a comprehensive R&D framework and an open innovation ecosystem, focusing on four key therapeutic areas: anti-infectives, oncology, digestive system, and central nervous system. Committed to developing differentiated and competitive medicines, kvvit Pharmaceutical has over 60 products in its pipeline, many of which are at the forefront of global innovation in cutting-edge therapeutic targets.
Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Established in 1976, Jiangxi Qingfeng Pharmaceutical is an innovative Chinese medicine enterprise under the Qingfeng Pharmaceutical Group, integrating R&D, production, and sales.
Leveraging modern scientific tools and methods, the company aims to meet unmet clinical needs by developing modern Chinese medicines. In 2023, its innovative Class 1.2 Chinese medicine,Aurantii Fructus Immaturus Total Flavonoids Tablets, was approved for market, filling a gap in the field of innovative Chinese medicine.
